Targeting Endoplasmic Reticulum Stress with Tauroursodeoxycholic Acid: A Potential Therapeutic Strategy for Allergic Airway Diseases
- 1School of Medicine, The Chinese University of Hong Kong, Shenzhen, China
Abstract
Background: Allergic airway diseases (AADs) such as asthma and allergic rhinitis impose a heavy global health burden, characterized by chronic airway inflammation, airway hyperresponsiveness, and structural remodeling. Endoplasmic reticulum (ER) stress has been increasingly identified as a key driver of AAD pathogenesis. As a well-characterized chemical chaperone, tauroursodeoxycholic acid (TUDCA) exhibits promising therapeutic potential for AADs by regulating immunity, relieving inflammation, and reversing airway pathological lesions.
Summary: This review summarizes how ER stress drives AAD development and progression of AADs and details the molecular mechanisms underlying the therapeutic effects of TUDCA by targeting ER stress-related unfolded protein response signaling pathways. Additionally, it highlights preclinical evidence supporting the efficacy of TUDCA and discusses the prospects and challenges associated with its clinical translation.
Key Messages: ER stress is a key pathogenic factor in AADs; TUDCA can target ER stress-related signaling pathways to exert therapeutic effects on AADs; preclinical studies confirm the efficacy of TUDCA, and its clinical translation may provide a novel ER stress-targeted strategy to optimize AAD management and improve patient outcomes.
Related
- Mechanisms and therapeutic prospects of short-chain fatty acids in neonatal hypoxic–ischemic encephalopathy via modulation of mitochondrial dysfunction and endoplasmic reticulum stress
- Targeting Endoplasmic Reticulum Stress With Exogenous GDNF Promotes Diabetic Corneal Epithelial and Neural Repair via PI3K/AKT Signaling.
- Hepatoprotective mechanism of tauroursodeoxycholic acid and its therapeutic potential in liver diseases
- PRKACA modulates endoplasmic reticulum stress-associated dysfunction in granulosa cell models relevant to polycystic ovary syndrome
- Polycystin-2 functions as a calcium leak channel under endoplasmic reticulum stress to protect against myocardial ischemia
BibTeX
@article{han2026targeting,
title = {{Targeting Endoplasmic Reticulum Stress with Tauroursodeoxycholic Acid: A Potential Therapeutic Strategy for Allergic Airway Diseases}},
author = {Yining Han},
journal = {Biomedicine Hub},
year = {2026},
month = oct,
doi = {10.1159/bmh/aboag006},
url = {https://doi.org/10.1159/bmh/aboag006},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting Endoplasmic Reticulum Stress with Tauroursodeoxycholic Acid: A Potential Therapeutic Strategy for Allergic Airway Diseases
AU - Yining Han
PY - 2026
DA - 2026/10/10
JO - Biomedicine Hub
DO - 10.1159/bmh/aboag006
UR - https://doi.org/10.1159/bmh/aboag006
AB - Background: Allergic airway diseases (AADs) such as asthma and allergic rhinitis impose a heavy global health burden, characterized by chronic airway inflammation, airway hyperresponsiveness, and structural remodeling. Endoplasmic reticulum (ER) stress has been increasingly identified as a key driver of AAD pathogenesis. As a well-characterized chemical chaperone, tauroursodeoxycholic acid (TUDCA) exhibits promising therapeutic potential for AADs by regulating immunity, relieving inflammation, and reversing airway pathological lesions. Summary: This review summarizes how ER stress drives AAD development and progression of AADs and details the molecular mechanisms underlying the therapeutic effects of TUDCA by targeting ER stress-related unfolded protein response signaling pathways. Additionally, it highlights preclinical evidence supporting the efficacy of TUDCA and discusses the prospects and challenges associated with its clinical translation. Key Messages: ER stress is a key pathogenic factor in AADs; TUDCA can target ER stress-related signaling pathways to exert therapeutic effects on AADs; preclinical studies confirm the efficacy of TUDCA, and its clinical translation may provide a novel ER stress-targeted strategy to optimize AAD management and improve patient outcomes.
SN - 2296-6870
ER -